196 related articles for article (PubMed ID: 30306872)
1. Combiphore (Structure and Ligand Based Pharmacophore) - Approach for the Design of GPR40 Modulators in the Management of Diabetes.
Gajjar KA; Gajjar AK
Curr Drug Discov Technol; 2020; 17(2):233-247. PubMed ID: 30306872
[TBL] [Abstract][Full Text] [Related]
2. CoMFA, CoMSIA and HQSAR Analysis of 3-aryl-3-ethoxypropanoic Acid Derivatives as GPR40 Modulators.
Gajjar KA; Gajjar AK
Curr Drug Discov Technol; 2020; 17(1):100-118. PubMed ID: 30160214
[TBL] [Abstract][Full Text] [Related]
3. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875.
Srivastava A; Yano J; Hirozane Y; Kefala G; Gruswitz F; Snell G; Lane W; Ivetac A; Aertgeerts K; Nguyen J; Jennings A; Okada K
Nature; 2014 Sep; 513(7516):124-7. PubMed ID: 25043059
[TBL] [Abstract][Full Text] [Related]
4. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
Chen C; Li H; Long YQ
Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
[TBL] [Abstract][Full Text] [Related]
5. Ligand-based pharmacophore detection, screening of potential gliptins and docking studies to get effective antidiabetic agents.
Agrawal R; Jain P; Dikshit SN
Comb Chem High Throughput Screen; 2012 Dec; 15(10):849-76. PubMed ID: 23140189
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for GPR40 allosteric agonism and incretin stimulation.
Ho JD; Chau B; Rodgers L; Lu F; Wilbur KL; Otto KA; Chen Y; Song M; Riley JP; Yang HC; Reynolds NA; Kahl SD; Lewis AP; Groshong C; Madsen RE; Conners K; Lineswala JP; Gheyi T; Saflor MD; Lee MR; Benach J; Baker KA; Montrose-Rafizadeh C; Genin MJ; Miller AR; Hamdouchi C
Nat Commun; 2018 Apr; 9(1):1645. PubMed ID: 29695780
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel G-protein-coupled receptor 40 (GPR40) agonists by hybrid
Nath V; Ahuja R; Kumar V
J Biomol Struct Dyn; 2019 Sep; 37(14):3764-3787. PubMed ID: 30252605
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore-based virtual screening approach for identification of potent natural modulatory compounds of human Toll-like receptor 7.
Gupta CL; Babu Khan M; Ampasala DR; Akhtar S; Dwivedi UN; Bajpai P
J Biomol Struct Dyn; 2019 Nov; 37(18):4721-4736. PubMed ID: 30661449
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore-guided repurposing of fibrates and retinoids as GPR40 allosteric ligands with activity on insulin release.
Cione E; Caroleo MC; Kagechika H; Manetti F
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):377-383. PubMed ID: 33525941
[TBL] [Abstract][Full Text] [Related]
10.
Vink G; Nebel JC; Wren SP
Future Med Chem; 2021 Apr; 13(8):691-700. PubMed ID: 33715419
[No Abstract] [Full Text] [Related]
11. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2
Musoev A; Numonov S; You Z; Gao H
Molecules; 2019 Aug; 24(16):. PubMed ID: 31394858
[TBL] [Abstract][Full Text] [Related]
13. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
14. GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
Mancini AD; Poitout V
Diabetes Obes Metab; 2015 Jul; 17(7):622-9. PubMed ID: 25604916
[TBL] [Abstract][Full Text] [Related]
15. Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches.
Jana S; Singh SK
J Biomol Struct Dyn; 2019 Mar; 37(4):944-965. PubMed ID: 29475408
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophore modeling, comprehensive 3D-QSAR, and binding mode analysis of TGR5 agonists.
Sindhu T; Srinivasan P
J Recept Signal Transduct Res; 2017 Apr; 37(2):109-123. PubMed ID: 27267434
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a novel potent GPR40 full agonist.
Meegalla SK; Huang H; Martin T; Xu J; Zhao S; Liu J; Hall M; Gunnet J; Wang Y; Rady B; Silva J; Otieno M; Arnoult E; Paul Lee S; Pocai A; Player MR
Bioorg Med Chem Lett; 2018 Feb; 28(4):720-726. PubMed ID: 29366647
[TBL] [Abstract][Full Text] [Related]
18. Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes.
Burant CF
Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S175-9. PubMed ID: 23882043
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR Based Pharmacophore Modeling and Virtual Screening for Identification of Novel G Protein-Coupled Receptor40 Agonists.
Lu P; Wang Y; Ouyang P; She J; He M
Curr Comput Aided Drug Des; 2015; 11(1):51-6. PubMed ID: 26022066
[TBL] [Abstract][Full Text] [Related]
20. G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes.
Choi YJ; Shin D; Lee JY
Arch Pharm Res; 2014 Apr; 37(4):435-9. PubMed ID: 24234912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
